tldrdaily.news logo
Tag

Elahere

All articles tagged with #elahere

healthcare2 years ago

AbbVie Bolsters Solid Tumor Portfolio with ImmunoGen Acquisition and ELAHERE® Cancer Therapy

AbbVie has announced its acquisition of ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. The acquisition will expand AbbVie's solid tumor portfolio and accelerate its entry into the commercial market for ovarian cancer. The transaction is valued at approximately $10.1 billion and is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.

via AbbVie|
#abbvie#acquisition#cancer-therapy
healthcare2 years ago

Biotech Stocks Soar on Positive Cancer Study Results

ImmunoGen's drug, Elahere, lowered the risk of disease progression or death by 35% in a specific group of patients with ovarian cancer, while Day One Biopharmaceuticals' drug, Tovarafenib, showed a 67% response rate in pediatric brain tumors. Replimune's skin cancer treatment showed a 37% response rate in melanoma patients. Gilead Sciences and Arcus Biosciences' lung cancer treatment showed a median of 9.3 to 9.9 months before worsening.

via Investor's Business Daily|
#cancer-treatment#day-one-biopharmaceuticals#elahere
healthcare2 years ago

New Cancer Drugs Show Promising Results in Improving Survival and Reducing Disease Progression.

ImmunoGen's ELAHERE has demonstrated a 35% reduction in the risk of disease progression or death compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC), according to results from the Phase 3 confirmatory MIRASOL trial. ELAHERE is the first treatment to show an overall survival benefit in this patient population. The data further support the potential of ELAHERE to become the new standard of care for patients with FRα-positive platinum-resistant ovarian cancer.

via Yahoo Finance|
#chemotherapy#clinical-trial#elahere
biotech2 years ago

ImmunoGen's Ovarian Cancer Drug Shows Promising Results, Stock Skyrockets.

Biotech company ImmunoGen's stock soared 136% after reporting "significant and clinically meaningful" survival results in a phase 3 trial of its Elahere treatment for platinum-resistant ovarian cancer. The drug reduced the risk of death by 33% and showed a statistically significant improvement in progression-free survival compared with chemotherapy. ImmunoGen plans to submit a marketing authorization application in Europe and a supplemental Biologics License Application in the U.S. for a conversion to a regular approval of Elahere. The drug was granted accelerated approval by the FDA in November.

via Barron's|
#biotech#drug-trial#elahere
healthcare2 years ago

ImmunoGen's Elahere shows promise in treating ovarian cancer, stock surges.

ImmunoGen's ovarian cancer drug, Elahere, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared to chemotherapy for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer patients who have received therapy. The company plans to submit an MAA to the European Medicines Agency and an sBLA to the FDA in the second half of this year. As a result, ImmunoGen's stock soared by 112.46%.

via Yahoo Finance|
#elahere#european-medicines-agency#fda
healthcare2 years ago

ImmunoGen's Elahere delivers positive results in ovarian cancer trial, stock soars.

ImmunoGen's experimental ovarian cancer drug, Elahere, helped extend the lives of patients and significantly prolonged the time that a patient lives without the cancer worsening, according to a late-stage trial. The US FDA had earlier given accelerated approval for Elahere, based on data from a single-arm trial. The company plans to submit a marketing application in Europe and a supplemental application in the US for the conversion to a regular approval by the second half of the year. Shares of the drug developer jumped to a near five-year high of $11.95 on Wednesday.

via Reuters|
#cancer-drug#clinical-trial#elahere